The U.S. Dairy Research Institute (Rosemont, IL) hailed these primary findings, noting in a press release that the benefits of dairy on type 2 diabetes risk could be related to improved glucose tolerance.
An analysis of food frequency questionnaires from the historical Women’s Health Initiative has linked low-fat dairy and yogurt consumption to reduced risk of type 2 diabetes development. The research is now available in the Journal of Nutrition.
The 1991 Women’s Health Initiative provided data sets and clinical trials on over 82,000 postmenopausal women.
University and public hospital researchers looked for associations between dairy and yogurt consumption and type 2 diabetes risks. After adjusting for confounding variables, low-fat dairy and yogurt, regardless of fat level, were both associated with decreased risk of type 2 diabetes. The link between dairy consumption and reduced risk was most pronounced in women with high body mass index (BMI).
“Given that there is no clear mechanism for the inverse association of low-fat dairy product or yogurt consumption and type 2 diabetes, it is worth considering the possibility that our findings result from unmeasured or residual confounding despite extensive adjustment for other dietary variables and risk factors for diabetes,” warned the researchers.
The U.S. Dairy Research Institute (Rosemont, IL) hailed these primary findings, noting in a press release that the benefits of dairy on type 2 diabetes risk could be related to improved glucose tolerance. The group has compiled a growing body of evidence on the potential relationship between dairy and diabetes.
This Women’s Health Initiative analysis was funded by NIH, the U.S. Department of Health and Human Services, and the National Health, Lung, and Blood Institute.
The impact of GLP-1 on supplements, functional foods, and retail: a webinar from CRN
January 29th 2025The recent CRN webinar discussed GLP-1 medications' impact on supplements, functional foods, and retail, covering consumer trends, global market insights, retailer strategies, industry implications, and future opportunities for innovation.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.